Head-to-head evidence
SYR-472 vs Yogliptin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: DPP-4 · full Type 2 Diabetes pipeline
SYR-472
Developed by Takeda Pharmaceutical Company
NCT02324569 · Phase 3 · completed
The 12-week comparison randomized 240 participants and used quadruple blinding with placebo control. The primary HbA1c endpoint was met, with a statistically significant treatment difference, but HbA1c is a surrogate laboratory measure rather than a hard clinical endpoint; the subsequent long-term period was open-label.
Yogliptin
Developed by Chengdu Easton Biopharmaceuticals
NCT05318326 · Phase 3 · status unknown
The trial randomly assigns patients to Yogliptin or a matching placebo and blinds patients, care providers, investigators and outcome assessors alike, using HbA1c change, the standard regulator-accepted measure for diabetes drugs, as its main result. Results have not been posted yet, so whether Yogliptin lowered blood sugar significantly more than placebo is not yet known.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: SYR-472's landscape · Yogliptin's landscape